Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome
/in News /by 3mediawebhttps://www.thestreet.com/story/14280950/1/epygenix-therapeutics-receives-us-fda-orphan-drug-designation-for-epx-300-for-the-treatment-of-patients-with-dravet-syndrome.html
/in News /by 3mediawebhttps://www.newswire.com/news/epygenix-therapeutics-receives-orphan-drug-designation-from-the-u-s-19369643
/in News /by 3mediawebhttp://abc7news.com/health/fish-larvae-being-used-to-help-children-with-epilepsy/1847815/
/in News /by 3mediawebhttps://www.nih.gov/news-events/news-releases/epilepsy-drug-discovered-fish-model-shows-promise-small-pediatric-clinical-trial
/in News /by Lysa Millerhttps://www.ucsf.edu/news/2017/01/405491/through-looking-glass-quest-parents-and-scientists-end-pediatric-epilepsy
/in News /by Lysa MillerAbout Epygenix
Epygenix Therapeutics, Inc. is developing precision medicine for rare and catastrophic forms of genetic epilepsy, such as Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, and Otahara syndrome.
How To Find Us
Epygenix Therapeutics
140 E. Ridgewood Ave.
Suite 415, South Tower
Paramus, NJ 07652
Phone: 1 (201) 940-7377
Fax: 1 (201) 940-7218
info@epygenix.com
Latest News
- Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
- Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome
- Epygenix Therapeutics Receives US FDA Orphan Drug Designation For EPX-300 For The Treatment Of Patients With Dravet Syndrome.
- A New School of Drug Discovery